Aligos Therapeutics EASL 2026 HBV Combination Data: ALG-170675 ASO Synergizes With Pevifoscorvir Sodium; 40% of HBeAg+ Patients Reach HBsAg Levels Qualifying for ASO Therapy at Week 48
Aligos Therapeutics presented additional EASL 2026 data on its chronic hepatitis B (HBV) combination strategy. An analog of ALG-170675, a potential best-in-class antisense oligonucleotide (ASO), demonstrated additive-to-synergistic effects when combined with ALG-001075 (the active parent moiety of pevifoscorvir sodium, a capsid assembly modulator). Separately, 40% of HBeAg-positive chronic HBV patients treated with pevifoscorvir sodium for 48 weeks reached HBsAg reductions low enough to potentially qualify for ASO treatment — supporting a sequencing strategy toward functional HBV cure where the capsid modulator lowers viral antigen load before the ASO finishes the job. The data complements the ALG-055009 THR-β MASH results (46.2% liver-fat reduction) Aligos presented earlier in the week. The combination-and-sequencing approach mirrors the broader trend in liver disease toward layered mechanisms rather than single-agent therapy, and positions Aligos across the HBV, HDV, and MASH liver-disease franchises.